We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
The current ZNTL market cap is 835.91M. The company's latest EPS is USD -4.1177 and P/E is -2.89.
| Quarter End | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 0 | 0 | 0 | 0 | 0 |
| Operating Income | -54.19M | -68.04M | -67.26M | -117.62M | -57.77M |
| Net Income | -54.4M | -54.97M | -63.22M | -112.53M | -55.53M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 0 | 0 | 0 | 0 | 0 |
| Operating Income | -46.85M | -118.79M | -209.57M | -243.57M | -315.52M |
| Net Income | -45.66M | -117.84M | -158.73M | -236.81M | -292.19M |
| Quarter End | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 529.19M | 539.31M | 489.34M | 621.44M | 585.72M |
| Total Liabilities | 100.46M | 105.29M | 103.68M | 98.16M | 103.82M |
| Total Equity | 428.74M | 434.02M | 385.67M | 523.28M | 481.9M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 87.48M | 365.56M | 454.51M | 539.31M | 551.69M |
| Total Liabilities | 19.06M | 32.18M | 90.03M | 105.29M | 114.3M |
| Total Equity | -73.29M | 333.38M | 364.48M | 434.02M | 437.39M |
| Quarter End | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | -126.42M | -163.75M | -49.28M | -128.56M | -167.22M |
| Investing | -102.29M | -114.18M | 42.12M | 115.05M | -2.4M |
| Financing | 211.3M | 261.04M | 373k | 236.99M | 237.3M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | -39.14M | -86.83M | -154.09M | -163.75M | -207.82M |
| Investing | -352k | -284.83M | -18.12M | -114.18M | -44.46M |
| Financing | 81.83M | 360.44M | 178.52M | 261.04M | 237.3M |
| Market Cap | 835.91M |
| Price to Earnings Ratio | -2.89 |
| Price to Sales Ratio | 0 |
| Price to Cash Ratio | 30.14 |
| Price to Book Ratio | 1.93 |
| Dividend Yield | - |
| Shares Outstanding | 70.96M |
| Average Volume (1 week) | 676.66k |
| Average Volume (1 Month) | 710.05k |
| 52 Week Change | -45.06% |
| 52 Week High | 31.46 |
| 52 Week Low | 9.56 |
| Spread (Intraday) | 0.05 (0.42%) |
| Company Name | Zentalis Pharmaceuticals Inc |
| Address |
251 little falls drive wilmington, delaware 19808 |
| Website | https://www.zentalis.com |
| Industry | pharmaceutical preparations (2834) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
